Page 25 - Towards personalized therapy for metastatic prostate cancer: technical validation of [18F]fluoromethylcholine

27. Yaqub M, Oprea-Lager DE, Hofman M and Boellaard R. Methodological aspects of PET/MR imaging. Tijdschr
v Nucl Geneesk. 2013;35:1153–1159 1
Introduction and outline of the thesis
28. Basu S, Zaidi H and Alavi A. Clinical and research applications of quantitative PET imaging. PET Clin. 2007;161–172
29. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015; 42:328–354
30. Jadvar H and Colleti PM. Competitive advantage of PET/MRI. Eur J Radiol. 2013;doi 10.016/j.ejrad.2013.05.028
31. Price DT, Coleman RE, Liao RP, et al. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol.
2002;168:273–280
32. Bauman G, Belhocine T, Kovacs M, et al. 18F-fluorocholine for prostate cancer imaging: a systematic review of
the literature. Prostate Cancer Prostatic Dis. 2012;15:45–55
33. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as
oncologic PET tracers. J Nucl Med. 2001;42:1805–1814
34. Fuccio C, Rubello D, Castellucci P, et al. Choline PET/CT for prostate cancer: main clinical applications. Eur J
Radiol. 2011;80:e50–e56
35. Picchio M, Briganti A, Fanti S, et al. The role of choline positron emission tomography/computed tomography
in the management of patients with prostate-specific antigen progression after radical treatment of prostate
cancer. Eur Urol. 2011;59:51–60
36. Reske SN, Blumstein NM, Neumaier B, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med.
2006;47:1249–1254
37. Roivainen A, Forsback S, Gronroos T, et al. Blood metabolism of [methyl-11C]choline; implications for in vivo
imaging with positron emission tomography. Eur J Nucl Med. 2000;27:25–32
38. Sutinen E, Nurmi M, Roivainen A, et al. Kinetics of [11C]choline uptake in prostate cancer: a PET study. Eur J
Nucl Med Mol Imaging. 2004;31:317–324
39. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med. 2011;52:81–
89
40. Uusijarvi H, Nilsson LE, Bjartell A and Mattsson S. Biokinetics of 18F-choline studied in four prostate cancer
patients. Radiat Prot Dosimetry. 2010;139:240–244
41. Igerc I, Kohlfürst S, Gallowitsch HJ, et al. The value of 18F-choline PET/CT in patients with elevated PSA-
level and negative prostate needle biopsy for localization of prostate cancer. Eur J Nucl Med Mol Imaging.
2008;35:976–983
42. Kwee SA, Coel MN, Lim J and Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron
emission tomography. J Urol. 2005;173:252–255
43. Evangelista L, Zattoni F, Guttilla A, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer —
a systematic review and meta-analysis. Clin Nucl Med. 2013;38:305–314
44. DeGrado TR, Reiman RE, Price DT, et al. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J
Nucl Med. 2002;43:92–96
45. Verwer EE, Oprea-Lager DE, van den Eertwegh AJ, et al. Quantification of 18F-fluorocholine kinetics in patients
with prostate cancer. J Nucl Med. 2015;56:365–371
46. Tavola F, Janzen T, Giussani A, et al. Nonlinear compartmental model of 18F-choline. Nucl Med Biol.
2012;39:261–268
47. Scher HI, Morris MJ, Basch E and Heller G. End points and outcomes in castration-resistant prostate cancer:
from clinical trials to clinical practice. J Clin Oncol. 2011;29:3695–3704
48. Lilja H, Ulmert D and Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and
monitoring. Nat Rev Cancer. 2008;8:268–278
49. Wahl RL, Jacene H, Kasamon Y and Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET
response criteria in solid tumors. J Nucl Med. 2009;50 (Suppl 1):122S–150S
50. Costelloe CM, Chuang HH, Madewell JE and Ueno NT. Cancer response criteria and bone metastases: RECIST
1.1, MDA and PERCIST. J Cancer. 2010;1:80–92
51. Wallace TJ, Torre T, Grob M, et al. Current approaches, challenges and future directions for monitoring
treatment response in prostate cancer. J Cancer. 2014;5:3–24
52. Müller SA, Holzapfel K, Seidl C, et al. Characterization of choline uptake in prostate cancer cells following
bicalutamide and docetaxel treatment. Eur J Nucl Med Mol Imaging. 2009;36:1434–1442
53. Oprea-Lager DE, van Kanten MP, van Moorselaar RJ, et al. [18F]fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells. Mol imaging Biol. 2015;17:319–327
23